Blockade of mast cell histamine secretion in response to neurotensin by SR 48692, a nonpeptide antagonist of the neurotensin brain receptor.

Br J Pharmacol. 1995 April; 114(7): 1466–1470.

PMCID: PMC1510300

L A Miller, D E Cochrane, R E Carraway, and R S Feldberg

Department of Biology, Tufts University, Medford, MA 02155, USA.

This article has been cited by other articles in PMC.

Abstract

1. Pretreatment of rat isolated mast cells with SR 48692, a nonpeptide antagonist of the neurotensin (NT) receptor, prevented histamine secretion in response to NT. 2. This inhibition was rapid in onset (approximately 1 min) and dependent upon the concentration of SR 48692 (IC50 approximately 1-10 nM). 3. SR 48692 (1-1000 nM) did not inhibit histamine secretion elicited by substance P, bradykinin or compound 48/80, or by anti-IgE stimulation of sensitized mast cells. 4. When SR 48692 was injected intradermally (5 pmol in 50 microliters) into anaesthetized rats, 15 min before the intradermal injection of NT, it reduced the effect of NT on vascular permeability. 5. When injected intravenously, SR 48692 attenuated the effects of NT on haematocrit and blood stasis. 6. These results demonstrate that SR 48692 selectively antagonizes the actions of NT on rat isolated mast cells as well as mast cells in vivo. Given the demonstrated specific interaction of SR 48692 with receptors for NT in brain, our results suggest the presence of specific NT receptors on mast cells.

Full text

Full text is available as a scanned copy of the original print version. Get a printable copy (PDF file) of the complete article (902K), or click on a page image below to browse page by page. Links to PubMed are also available for Selected References.

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

Aridor, M; Rajmilevich, G; Beaven, MA; Sagi-Eisenberg, R. Activation of exocytosis by the heterotrimeric G protein Gi3. Science. 1993 Dec 3;262(5139):1569–1572. [PubMed]
Aridor, M; Traub, LM; Sagi-Eisenberg, R. Exocytosis in mast cells by basic secretagogues: evidence for direct activation of GTP-binding proteins. J Cell Biol. 1990 Sep;111(3):909–917. [PubMed]
Bueb, JL; Mousli, M; Bronner, C; Rouot, B; Landry, Y. Activation of Gi-like proteins, a receptor-independent effect of kinins in mast cells. Mol Pharmacol. 1990 Dec;38(6):816–822. [PubMed]
Carraway, RE; Cochrane, DE; Boucher, W; Mitra, SP. Structures of histamine-releasing peptides formed by the action of acid proteases on mammalian albumin(s). J Immunol. 1989 Sep 1;143(5):1680–1684. [PubMed]
Carraway, RE; Cochrane, DE; Granier, C; Kitabgi, P; Leeman, E; Singer, EA. Parallel secretion of endogenous 5-hydroxytryptamine and histamine from mast cells stimulated by vasoactive peptides and compound 48/80. Br J Pharmacol. 1984 Feb;81(2):227–229. [PubMed]
Carraway, R; Cochrane, DE; Lansman, JB; Leeman, SE; Paterson, BM; Welch, HJ. Neurotensin stimulates exocytotic histamine secretion from rat mast cells and elevates plasma histamine levels. J Physiol. 1982 Feb;323:403–414. [PubMed]
Carraway, RE; Cochrane, DE; Salmonsen, R; Muraki, K; Boucher, W. Neurotensin elevates hematocrit and plasma levels of the leukotrienes, LTB4, LTC4, LTD4 and LTE4, in anesthetized rats. Peptides. 1991 12(5):1105–1111.Sep–Oct; [PubMed]
Carraway, R; Leeman, SE. The isolation of a new hypotensive peptide, neurotensin, from bovine hypothalami. J Biol Chem. 1973 Oct 10;248(19):6854–6861. [PubMed]
Carraway, RE; Mitra, SP; Cochrane, DE. Structure of a biologically active neurotensin-related peptide obtained from pepsin-treated albumin(s). J Biol Chem. 1987 May 5;262(13):5968–5973. [PubMed]
Church, MK; Lowman, MA; Rees, PH; Benyon, RC. Mast cells, neuropeptides and inflammation. Agents Actions. 1989 Apr;27(1-2):8–16. [PubMed]
Cochrane, DE. Peptide regulation of mast-cell function. Prog Med Chem. 1990;27:143–188. [PubMed]
Cochrane, DE; Carraway, RE; Boucher, W; Feldberg, RS. Rapid degradation of neurotensin by stimulated rat mast cells. Peptides. 1991 12(6):1187–1194.Nov–Dec; [PubMed]
Cochrane, DE; Douglas, WW. Calcium-induced extrusion of secretory granules (exocytosis) in mast cells exposed to 48-80 or the ionophores A-23187 and X-537A. Proc Natl Acad Sci U S A. 1974 Feb;71(2):408–412. [PubMed]
Fewtrell, CM; Foreman, JC; Jordan, CC; Oehme, P; Renner, H; Stewart, JM. The effects of substance P on histamine and 5-hydroxytryptamine release in the rat. J Physiol. 1982 Sep;330:393–411. [PubMed]
Gully, D; Canton, M; Boigegrain, R; Jeanjean, F; Molimard, JC; Poncelet, M; Gueudet, C; Heaulme, M; Leyris, R; Brouard, A, et al. Biochemical and pharmacological profile of a potent and selective nonpeptide antagonist of the neurotensin receptor. Proc Natl Acad Sci U S A. 1993 Jan 1;90(1):65–69. [PubMed]
Jasani, B; Kreil, G; Mackler, BF; Stanworth, DR. Further studies on the structural requirements for polypeptide-mediated histamine release from rat mast cells. Biochem J. 1979 Sep 1;181(3):623–632. [PubMed]
Kitabgi, P; Checler, F; Mazella, J; Vincent, JP. Pharmacology and biochemistry of neurotensin receptors. Rev Clin Basic Pharm. 1985 5(3-4):397–486.Jul–Dec; [PubMed]
Mazurek, N; Pecht, I; Teichberg, VI; Blumberg, S. The role of the N-terminal tetrapeptide in the histamine releasing action of substance P. Neuropharmacology. 1981 Nov;20(11):1025–1027. [PubMed]
Miller, LA; Cochrane, DE; Carraway, RE; Feldberg, RS. Inhibitory effects of the neurotensin8-13 analogs Asp13-NT8-13 and Asp12-NT8-13 on mast cell secretion. Agents Actions. 1993 Jan;38(1-2):1–7. [PubMed]
Mousli, M; Bronner, C; Bockaert, J; Rouot, B; Landry, Y. Interaction of substance P, compound 48/80 and mastoparan with the alpha-subunit C-terminus of G protein. Immunol Lett. 1990 Sep;25(4):355–357. [PubMed]
Mousli, M; Bueb, JL; Bronner, C; Rouot, B; Landry, Y. G protein activation: a receptor-independent mode of action for cationic amphiphilic neuropeptides and venom peptides. Trends Pharmacol Sci. 1990 Sep;11(9):358–362. [PubMed]
Pearce, FL; Kassessinoff, TA; Liu, WL. Characteristics of histamine secretion induced by neuropeptides: implications for the relevance of peptide-mast cell interactions in allergy and inflammation. Int Arch Allergy Appl Immunol. 1989;88(1-2):129–131. [PubMed]
Prange, AJ., Jr The manifold actions of neurotensin, a trophotropic agent. Ann N Y Acad Sci. 1992;668:298–306. [PubMed]
Reinecke, M. Neurotensin. Immunohistochemical localization in central and peripheral nervous system and in endocrine cells and its functional role as neurotransmitter and endocrine hormone. Prog Histochem Cytochem. 1985;16(1):1–172. [PubMed]
Repke, H; Bienert, M. Mast cell activation--a receptor-independent mode of substance P action? FEBS Lett. 1987 Sep 14;221(2):236–240. [PubMed]
Rioux, F; Kérouac, R; St-Pierre, S. Characterization of the histamine releasing effect of neurotensin in the rat heart. Peptides. 1985 6(1):121–125.Jan–Feb; [PubMed]
Sagi-Eisenberg, R; Ben-Neriah, Z; Pecht, I; Terry, S; Blumberg, S. Structure-activity relationship in the mast cell degranulating capacity of neurotensin fragments. Neuropharmacology. 1983 Feb;22(2):197–201. [PubMed]
Seybold, VS; Treder, BG; Aanonsen, LM; Parsons, A; Brown, DR. Neurotensin binding sites in porcine jejunum: biochemical characterization and intramural localization. Synapse. 1990;6(1):81–90. [PubMed]
Shanahan, F; Denburg, JA; Fox, J; Bienenstock, J; Befus, D. Mast cell heterogeneity: effects of neuroenteric peptides on histamine release. J Immunol. 1985 Aug;135(2):1331–1337. [PubMed]
Vincent, JP. Neurotensin receptors. Binding properties, transduction mechanisms, and purification. Ann N Y Acad Sci. 1992;668:90–100. [PubMed]